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Summary 
 
The protozoan parasites Entamoeba histolytica and Giardia intestinalis present 
important health problems worldwide. E. histolytica causes amoebic colitis and liver 
abscess with an incidence around 40 million infections per year and up to 100,000 
deaths. G. intestinalis causes around 280 million symptomatic infections every year 
and due to the persistent diarrhea, has a high morbidity rate among children. The 
drug of choice for treatment of both parasites, for more than 40 years, is 
metronidazole. However, this drug also possesses adverse properties such as 
potential teratogenicity and central nervous system toxicity.  
    In order to identify new agents with activity against E. histolytica or G. intestinalis, 
fourteen compounds isolated from tropical plants, from Rutaceae, Meliaceae and 
Stemonaceae families, were tested for their activity against these parasites. The 
parasites were grown in 96 well microtiter plates, placed in air-tight plastic boxes, in 
which anaerobic conditions were established. The isolated compounds were 
examined in quick tests at concentrations of 1 µg/ml and 20 µg/ml. After 24 h and 48 
h, life and dead cells were stained and counted. 
    Only one out of fourteen compounds showed activity against both parasites,  
methylgerambullin, a sulphur-containing amide, isolated from Glycosmis mauritiana. 
Additional testing showed, for example, an EC50 of 6.09 µg/ml for anti-amoebic 
activity and 6.14 µg/ml for anti-giardial activity after 24 h of treatment. We found that 
the activity was lower in freshly prepared media, and linked this effect to the level of 
reduced cysteine in the medium. This led us to believe that chemical reaction of the 
compound with thiol groups in the medium and in the parasite may be important for 
its mode of action.  
    Furthermore, the effect of methylgerambullin on the E. histolytica proteome was 
analysed by two-dimensional gel electrophoresis, which revealed four newly induced 
proteins. The proteins were identified by tandem mass spectrometry as isomers of 
alcohol dehydrogenase and pyruvate:ferredoxin oxidoreductase. These proteins 
were shifted towards a more acidic isoelectric point (pI), possibly due to 
phosphorylation of the proteins. Taken together, a new active agent was identified 
and initial information on its mode of action was gathered.  
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Zusammenfassung 
 
Die parasitischen Protozoen Entamoeba histolytica und Giardia intestinalis sind 
weltweit verbreitete Krankheitserreger. E. histolytica verursacht Amöbenruhr und 
Leberabzess mit etwa 40 Millionen Infizierten pro Jahr und bis zu 100.000 
Todesfällen. G. intestinalis verursacht jedes Jahr etwa 280 Millionen symptomatische 
Infektionen und eine hohe Morbidität unter Kindern mit chronischem Durchfall. Seit 
über 40 Jahren ist Metronidazol das Therapeutikum der Wahl zur Behandlung der 
beiden Parasiten. Allerdings hat dieses Medikament auch unerwünschte 
Eigenschaften wie zum Beispiel mögliche Teratogenität und Neurotoxizität.  
    Das Ziel dieser Arbeit war es, die Aktivität von vierzehn neu isolierten Naturstoffen 
gegen E. histolytica und G. intestinalis zu testen, die aus tropischen Pflanzen der 
Familien Rutaceae, Meliaceae und Stemonaceae isoliert waren. Die Parasiten 
wurden in 96-Loch  Mikrotiterplatten in luftdichten Plastikboxen unter anaeroben 
Bedingungen gezüchtet. Jede Substanz wurde zuerst in Schnelltests in den 
Konzentrationen von 1 µg/ml und 20 µg/ml getestet. Lebende und tote Zellen wurden 
nach 24 h und 48 h  angefärbt und gezählt. Nur eine der Substanzen zeigte eine 
Aktivität gegen die beiden Parasiten, Methylgerambullin, ein Schwefel enthaltendes 
Amid, das aus Glycosmis mauritiana isoliert war. In zusätzlichen Tests wurde zum 
Beispiel eine EC50 von 6,09 µg/ml für anti-Amöben und 6,14 µg/ml für anti-Giardien 
Aktivität für eine Behandlung von 24 h gefunden. Die Aktivität des 
Methylgerambullins war in frischem Medium niedriger und wir vermuteten, dass 
dieser Effekt  mit dem Gehalt von reduziertem Cystein in Medium zusammenhing. 
Deshalb könnte die chemische Reaktion zwischen Methylgerambullin und 
Thiolgruppen im Medium und in den Parasiten wichtig für den Wirkmechanismus 
sein. 
    Der Effekt des Methylgerambullins auf das E. histolytica Proteom wurde mittels 
zweidimensionaler Gelelektrophorese analysiert. Vier neue Spots in den behandelten 
Amöben wurden mittels Tandem-Massenspektrometrie als Isoformen von 
Alkoholdehydrogenase und Pyruvat:Ferredoxin Oxidoreduktase identifiziert. Beide 
Proteine waren in dem Gel zu einem saureren isoelektrischen Punkt verschoben, 
möglicherweise wegen Phosphorylierungen. Zusammenfassend wurde in dieser 
Arbeit eine neue aktive Substanz identifiziert und erste Informationen über ihren 
Wirkmechanismus wurden gewonnen. 
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1. Introduction 
 
1. 1.  Natural sources 
 
Since the beginning of mankind, people were relying on nature. On the one hand 
they tried to restrain it in order to make it more predictable and to build habitats and 
acreage by destroying it. On the other hand they were dependent on natural goods 
as sources of food, shelter and healing remedies. The ancient traditional medicine 
systems were based on plants, which have been used as powders and botanical 
potions to cure and prevent diseases (Raskin et al., 2002; Gurib-Fakim 2006). 
    During the evolution, plants, being non-mobile organisms, had to develop defense 
mechanisms against predators and diseases. At the same time they had to attract 
symbionts and protect themselves against other plants which were immediate 
competitors for the same resources in an ecosystem (Gurib-Fakim, 2006; Cseke et 
al., 2006; Gale et al., 2007). In order to achieve all that, besides primary products, 
such as carbohydrates, lipids, proteins, chlorophyll and nucleic acids, which are used 
for building and maintaining the cells, the plants were able to synthesize so-called 
secondary metabolites with a crucial role in ecophysiology of the plants as recently 
shown  (Briskin, 2000; Cseke et al., 2006). Most plant-derived bioactive compounds 
used in pharmacy, such as alkaloids, phenolics and terpenoids are, in fact, 
secondary metabolites of the plants (Raskin et al., 2002). 
    There is an estimation that 25% of the drugs prescribed nowadays are of plant 
origin as well as 11% of the 252 drugs, which are considered basic and essential by 
World Health Organization (WHO) (WHO, 1992; Rates, 2001).  However, knowing 
that there are 250,000 living plant species, only 5000 of which have been screened 
for their pharmacological activities until 1991, make us aware that the higher plants 
as a source of new drugs are still underestimated and poorly studied (Payne et al., 
1991; Rates, 2001). 
    Although there is a high predominance of single-ingredient drugs or so called new 
chemical entities (NCEs) in modern pharmaceutical industry, one has to keep in mind 
that there is a much greater diversity of bioactive compounds in the variety of plant 
species than in any artificially made chemical library. Therefore, natural compounds 
should be screened in order to find alternative treatments to failing medicinal 
products as well as to detect new drug candidates (Balandrin et al., 1993; Balunas 
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and Kinghorn 2005; Rocha et al., 2005; Chin et al., 2006; Gale et al., 2007; Butler, 
2004; Schmidt et al., 2007). 
 
 
1. 1. 2. Historical and current use of plant-derived substances 
 
Alkaloids 
 
The first written record about medicinal plants can be found around 5000 years B.C., 
on the cuneiform Mesopotamian tablet of the old Sumerians (Swerdlow, 2000). For 
centuries the surgeons have used extracts of opium and mandrake (Mandragora 
officinarum) as anesthetics prior to surgery or for the treatment of pain and 
sleeplessness (Carter, 1996, 2003). The opium is mentioned among other ancient 
medical texts, in the Ebes Papyri, around 1500 B.C. and texts of Greek’s 
pharmacologist and botanist Pedanius Discorides (40-90 A.D.) as well (Scholl, 2002; 
Carter, 2003). It was used in combination with mandrake all over the Old and New 
World, until 1874 when they were replaced with ether and then other modern 
anesthetics (Carter, 1996). Morphine, isolated from opium poppy (Papaver 
somniferum), was the first pure natural product used for therapy introduced for a wide 
commercial use by Merck Company in 1826 (Newman et al., 2000). Together with 
the other alkaloids isolated from the poppy plants narcotine, codeine, thebaine, 
papaverine and narceine, it is still applied as analgesic in modern medicine 
(Goldstein et al., 1974). 
    Many other alkaloids, in use today, have been used for centuries in traditional 
medicine, for example, galantamine, an acetylcholinesterase inhibitor, isolated from 
Galanthus nivalis (Howes et al., 2003). This plant was in use for neurological 
conditions by people in Caucasus Mountains in Russia and other Eastern European 
countries (Heinrich and Lee Teoh, 2004). Galantamine is currently one of only four 
drugs applied in treatment of Alzheimer’s disease (Chin et al., 2006; Prvulovic et al., 
2010). 
    Atropine, hyoscyamine and scopolamine, which are isolated from Atropa 
belladonna, Datura spp., Mandragora spp. and Brugmansia spp., the plants of which 
the sedative powers were described even in Shakespeare’s plays (Carter, 1996; 
Griffin and Lin, 2000), are in use as anticholinergics in western medicine (Balandrin 
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et al., 1993; Schmidt et al., 2007). Until replaced with tropicamide or phenylephrine, 
atropine was broadly used in ophthalmology as mydriatic, for a pupil dilatation, and 
cyclopegic, for a temporary paralysis of the accommodation reflexes (Kedvessy et al., 
1950). However, the atropine earned its place on the WHO’s Model list of essential 
medicines from 2005 because it is used for the treatment of bradycardia and asystole 
in cardiac arrest (Vincent, 1997; WHO, 2009). 
    Rauwolfia serpentina (Indian snakeroot) was for centuries an important part of 
Indian traditional medicine. The active alkaloids of the plant, namely, reserpine and 
rescinnamine reduce blood pressure (Thompson, 1956). 
    Psychotria ipecacuanha (coca bush), member of the Rubiaceae family, had been 
brought to Europe in 1658 from Brazil and ever since was used in treatment of some 
types of dysentery. In 1817 an active compound, the alkaloid emetine, was isolated 
from the root of the plant (Craig, 1934; Imperato, 1981). Despite negative side effects 
on the heart, emetine and its synthetically produced dehydroemetine, were the gold 
standard in treatment of amoebiasis caused by Entamoeba histolytica (Bianchi et al., 
1965; Brink et al., 1969), before the efficacy of metronidazole against the parasite 
was proven in 1966 (Powell et al., 1966). 
 
 
Figure 1: Psychotria ipecacuanha (Photo Pharmawiki.ch) 
 
    Other members of the Rubiaceae family that saved millions of lives, during three 
centuries of use, are Cinchona spp. The extracts from the bark of the cinchona tree 
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have antimalarial properties, due to the alkaloid quinine and its stereoisomer 
quinidine (Duran-Reynals, 1947; Bruce-Chwatt, 1987; Greenwood, 1992). Although 
isolated at the beginning of 19th century, quinine was not chemically synthesizable 
until 1944, so the whole amount of the treatment drug came directly from the tree 
barks (Kyle and Shampe, 1974). 
    One area of the pharmaceutical research that relies heavily on plants as possible 
sources of new drugs and treatments is anti-cancer research. It is estimated that over 
60% of anti-cancer agents, which are in use, are of natural origin. They are derived 
not only from plants, but from marine animals as well as from microorganisms (Cragg 
et al., 2005; Newman et al., 2003).  The breakthrough has happened when in the 
1950s so-called vinca alkaloids, vinblastine and vincristrine, were isolated from 
Catharanthus roseus (Madagascar periwinkle).They were shown to have anti-mitotic 
and anti-microtubule activity in cancer chemotherapy (Cragg et al., 1997; Takimoto 
and Calvo, 2008).  
 
Terpenoids 
 
In the field of anti-malaria treatment Artemisinin (qinghaosu) and its derivates are the 
most important drugs in use today. Artemisinin, a terpenoid, was isolated in 1972 
from Artemisia annua. The beneficial activity of Artemisia had been mentioned as 
early as 200 B.C. in “Prescriptions for Fifty-two Diseases” found in a Mawangdui Han 
dynasty tomb.  Extract of Artemisia annua was one of the cornerstones in traditional 
Chinese medicine (TCM) and its anti-malarial application was first reported in the 
fourth century in the “Handbook of Prescriptions for Emergencies” by Ge Hong. 
Although isolated in 1972 by Tu Youyou and proven to be the best and fastest 
existing antimalarial agent, it was not until 1979, when the findings were published in 
the Chinese medical journal that the rest of the world found out about it (Q.A.C.R.G., 
1979). 
    The terpenoids digitoxin and digoxin are secondary metabolites from Digitalis spp. 
(foxglove). As early as 1775, William Withering had identified foxglove as the active 
component of a polyherbal mixture able to reduce edema in patients with congestive 
heart failure, and foxglove and its active constituents have been in use ever since 
(Dewick, 2002). 
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Other compounds 
  
The National Cancer Institute (NCI) of the USA has founded a collection program 
with the U.S. Department of Agriculture (USDA), during which around 20,000 plant 
extracts were tested for anti-tumor activity in the period from 1957 to 1981. 
Unfortunately these samples were not screened for other pharmacological activities 
(Hamburger and Hostettmann, 1991; Rates, 2001).  However, within the program, in 
1967, Monroe E. Wall and Mansukh C. Wani have isolated antineoplastic paclitaxel 
(Taxol) from Taxus brevifolia (Pacific yew tree) (Wall et al., 1995; Wani et al., 1971; 
Cragg, 1998; Cragg and Newman, 2005). Paclitaxel is used for the treatment of 
ovarian, breast, lung, as well as head and neck cancer. It has also shown efficacy 
against Kaposi sarcoma and ability to prevent restenosis of coronary stents as anti-
proliferative agent (Heldman et al., 2001). 
    There are some other plant-derived compounds, which are in clinical development 
as possible anti-cancer agents. Triptolide from Tripterygium wilfordii, a plant well 
known in traditional Chinese medicine for treatment of variety of syndromes (Schmidt 
et al., 2007), has high cytostatic activity in different cell lines (Yang et al., 2003). 
Furthermore there is the group of combrestatins, isolated from Combretum caffrum 
(South African bush willow). C. caffrum was used in African and Indian traditional 
medicine, among others, for treatment of hepatitis and malaria. The combrestatins 
behave as anti-angiogenic agents, which by destroying the tumor’s vascular system 
cause its necrosis (Li and Sham, 2002; Pinney et al., 2005; Cragg and Newman, 
2005).  
 
1. 1. 3. Obstacles and challenges in drug discovery from plant-derived  
       substances 
 
As discussed above, plants and plant-derived substances played an enormous role 
in drug discovery. Some of the most important medicines today, such as quinine, 
artemisinin, atropine, morphine, and digoxin as well as the anti-cancer drugs 
paclitaxel, vincristrine and vinblastine are of plant origin. Even if the isolated 
substances do not serve as a drug, they very often provide a lead and serve as a 
model for development of the novel agents (Cragg and Newman, 2005). One of the 
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world wide best known drug, Bayer’s Aspirin, is a synthetic derivate of salicylic acid, 
originally isolated from the willow bark in 1897 (Raskin et al., 2002). 
    However, many pharmaceutical companies have dismissed their departments for 
natural product research, because the drug discovery from medicinal plants was 
regarded as more time and money consuming than other drug discovery methods 
(Butler, 2004; Koehn and Carter, 2005; Balunas and Kinghorn, 2005). It is estimated 
that only 1 in 10,000 tested compounds is promising for further development and only 
1 in 4 promising compounds is indeed approved as a new drug. This process takes 
on average 10 years (Williamson et al., 1996; Rates, 2001; Reichert, 2003)  and 
costs even more than 800 million dollars per successful development (Dickson and 
Gagnon, 2004; Balunas and Kinghorn, 2005). Furthermore, some drugs, even if they 
were active could not be chemically synthesized and had to be isolated from the 
plants. For example, before paclitaxel (Taxol) was chemically produced, 12,000 trees 
of T. brevifolia needed to be cut down in order to obtain 2.5 kg of Taxol (Hamburger 
and Hostettman, 1991; Wall and Wani, 1996; Rates, 2001). 
    Even with all these obstacles the experts predict that the plant-derived compounds 
will remain an essential component as basis for drug development, because it is 
believed that the diversity, complexity and richness of plant-isolated secondary 
metabolites are by far greater than those of chemically synthesized products 
(Balunas and Kinghorn, 2005; Schmidt et al., 2007). Nevertheless, considerable 
improvements in the field have to be made. Better and faster methodologies for plant 
collection, new technologies for compound isolation, as well as high-throughput 
bioassays are just some steps of the process, which need to be developed (Do and 
Bernard, 2004; Koehn and Carter, 2005; Butler, 2004; Balunas and Kinghorn, 2005). 
 
1. 1. 4. Current knowledge about the plants used in this study 
 
In this study, fourteen plant-derived substances were tested for their activity against 
the microaerophilic protozoa Entamoeba histolytica and Giardia intestinalis. 
Biologically they have been isolated from three different plant families: Asteraceae, 
Rutaceae and Meliaceae and chemically belong to six different classes of 
substances, namely sulphur-containing amides, a flavagline, acridones, a 
quinazoline, quinolines, and coumarines. Some of the compounds had been tested 
before, mostly for anti-cancer, anti-fungal or insecticidal activity.  
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    Sulphur-containing amides, namely, methylgerambullin, methyldambullin and 
sakambullin are isolated from the genus Glycosmis, family Rutaceae, which consists 
of around 40 species, all rich in various secondary metabolites (Greger et al., 1994; 
Hinterberger et al., 1998; Hofer et al., 2000). Some of these sulphur-containing 
amides have shown anti-fungal (Greger et al., 1993) or anti-cancer activity (Abdullah 
et al., 2006), so it is a fair assumption that they could have anti-parasitic activity as 
well. This has already been shown within our project for Trypanosoma cruzi 
(Astelbauer et al., 2010) and Leishmania infantum (Astelbauer et al., 2011). 
    Flavaglines, isolated from Aglaia species, family Meliaceae, were shown to have 
cytostatic activity (Proksch et al., 2005; Wu et al., 1997), and insecticidal activity 
(Greger et al., 2001; Schneider et al., 2000). The essential antifilarial drug ivermectin 
(WHO, 2009) has shown insecticidal activity as well (James et al., 1980), so it is 
worth analyzing is it vice versa with flavaglines.  
    Other compounds derived from Glycosmis spp. are the quinazoline arborine, the 
furoquinoline kokusagenine and the acridone arborinine, which all showed cytostatic 
activity (Rethy et al., 2008; Roseghini et al., 2006; Sohrab et al., 2004), as well as the 
furoquinolines dictamnine and iso-gama-fagarin, which showed anti-microbial activity 
(Bautz, 1994). 5-hydroxynoracronycine and yukocitrine are acridones isolated from 
both Glycosmis trichanthera and Atlantia rotundifolia, which previously have shown 
anti-plasmodial (Weniger et al., 2001) and anti-allergic activity (Chukaew et al., 
2008). 
    The coumarine microminutine derived from Micromelum minutum, another 
member of Rutaceae family, demonstrated cytostatic activity in vitro (Tantivatana et 
al., 1983). The coumarine, methyllacarol, isolated from Artemisia laciniata, 
Asteraceae family, and the pyranoquinoline zanthobungeanine, isolated from 
Glycosmis have not been analyzed prior to this study. 
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Figure 2: Overview of the fourteen compounds used in this study 
 
 
Sulphur-containing amides: 
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Methyldambullin, isolated from leaves of Glycosmis angustifolia (Greger et al., 1994). 
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Methylgerambullin, isolated from leaves of Glycosmis mauritiana (Greger et al., 1994;  
Hinterberger et al., 1998). 
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Sakambullin, isolated from leaves of Glycosmis chlorosperma (Hofer et al., 2000). 
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Flavagline and acridones: 
 
                                          
OH OH
C
OCH 3
O
OCH 3
H3CO
OCH 3
 
 
 
Aglafoline belongs to the flavagline class of compounds, isolated from rootbarks of 
Aglaia odorata, Aglaia australiensis and Aglaia coriacea (Engelmeier et al., 2000; 
Greger et al., 2001). 
 
 
 
                                   
N O
O
CH3
OH
OH
 
 
5-hydroxynoracronycine, acridone isolated from stembarks of Atalantia rotundifolia 
and Glycosmis trichantera (Vajrodaya et al., 1998). 
 
 
 
                                     
N O
O
CH3OH  
Yukocitrine, acridone isolated from stembarks of Atalantia rotundifolia and Glycosmis 
trichantera (Vajrodaya et al., 1998). 
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N
N
O
CH3  
 
Arborinine, acridone isolated from leaves of Glycosmis pentaphylla, Glycosmis 
sapindoides, Glycosmis parva and Glycosmis mauritiana (Greger et al., 1993; 
Mester, 1983). 
 
 
Quinazoline and quinolines: 
 
 
                                     
N
N
O
CH3  
 
Arborine, quinazoline isolated from leaves of Glycosmis pentaphylla (Rahmani et al., 
1992). 
 
                                     
N
O
OCH3 CH3
O
 
 
Zanthobungeanine, pyranoquinoline isolated from stembarks and rootbarks of 
Glycosmis puberula, Glycosmis cyanocarpa, Glycosmis pseudoracemosa and 
Zanthoxylum simulans (Brader et al., 1993). 
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                                     N
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Dictamnine, furoquinoline isolated from rootbarks of Glycosmis trichantera 
(Vajrodaya et al., 1998). 
 
 
                                     
N
O
O
CH3OCH3  
 
Iso-gamma-fagarine, furoquinoline isolated from leaves of Glycosmis citrifolia and 
Ruta graveolens (Bautz et al., 1994; Ito et al., 2000). 
 
 
                                  
H3CO
H3CO N O
OCH3
 
 
Kokusagenine, furoquinoline isolated from leaves of Glycosmis cyanocarpa, 
Glycosmis mauritiana, Glycosmis chlorosperma and Glycosmis sapinodoides (Greger 
et al., 1992; Pacher et al., 2001). 
 
 
 
 
 
 
 
 
 
 19
Coumarines: 
 
 
                                     
O OH3CO
O
O
 
 
Microminutine, isolated from fruits, leaves and stembark of Micromelum minutum 
(Tantivatana et al., 1983). 
  
 
                                 
O O
O
H3CO
OCH3
CH2OH 
 
Methyllacarol, isolated from leaves of Artemisia laciniata (Hofer et al., 1986; Szabo et 
al., 1985).  
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1. 2. Entamoeba histolytica 
 
Entamoeba histolytica is a microaerophilic protozoan and the causative agent of 
amoebiasis. 
 
 
Figure 3: E. histolytica trophozoite 
 
1. 2. 1. Historical overview 
 
It was reported at the beginning of the 19th century that Indian physicians can 
differentiate between several types of dysentery (Ballingall, 1818; Imperato, 1981), 
and though there were numerous reports about parasites in the stool of dysenteric 
patients, it wasn’t until 1875 that Entamoeba histolytica was studied in detail by a 
Russian physician Fedor Lösch. He examined a patient with intestinal amoebiasis, 
the content of the patient’s stool, and gave a detailed description of the parasite, 
which he named Amoeba coli, its structure, size, motility, vacuoles, nucleus, and he 
documented his observations by drawings. He also performed an experiment in 
which four dogs were infected, and one of them became ill. Because of the different 
course of the dog’s disease, which was rather mild in comparison to patient’s 
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disease, Lösch concluded wrongly that amoebae sustain the disease, but are not 
causing it (Lösch, 1875; Imperato, 1981). 
    In 1893 Quincke and Roos described the cyst form of the amoebae and also 
noticed that the vegetative form causes dysentery when injected into the rectum of 
kittens, but does not cause the disease when its given orally (Quincke and Roos, 
1893). Huber in 1903 first noticed four nuclei in amoebic cysts (Huber, 1903; 
Imperato, 1981). 
     Strong and then Schaudinn differentiated between pathogenic and non-
pathogenic amoebae. The disease-causing amoeba was named Entamoeba 
histolytica by Schaudinn because of its tissue destroying ability and the harmless one 
Entamoeba coli Lösch (Schaudinn, 1903; Imperato, 1981). 
    This was confirmed by Walker and Sellards in 1913, which demonstrated not only 
the differences between E. histolytica and E. coli, but also the fact that infection with 
E. histolytica does not always develop into clinical disease and that infection is 
caused by the cyst of the parasite (Walker and Sellards, 1913). 
    In 1925 Emile Brumpt suggested that humans can be infected with two different 
but morphologically identical species, one pathogenic, namely Entamoeba histolytica 
and the other non-pathogenic, which he named Entamoeba dispar (Brumpt, 1925). 
However, there was no way to distinguish the two species, so the theory was 
dismissed until 53 years later when Sargeaunt and Williams (1978) showed that the 
two species can be differentiated on the basis of isoenzyme typing. Since then other 
biochemical, immunological and genetic evidence was emerging, and in 1993 a 
formal redescription of E. histolytica by Diamond and Clark and separation from E. 
dispar occurred (Diamond and Clark, 1993). This was formally accepted by the World 
Health Organization in 1997 (WHO, Report of the Expert Consultation on 
Amoebiasis, 1997). 
    In 2005 the sequencing of the Entamoeba histolytica genome was reported, as a 
result of cooperation of a large number of Entamoeba research groups (Loftus et al., 
2005). 
    The first in vitro cultivation of E. histolytica was preformed with blood agar plates, 
which contained a single species of bacteria. The cultivation was done by Musgrave 
and Clegg, which also established the term “amoebiasis” for the disease caused by 
the parasite (Musgrave and Clegg, 1904). Boeck and Drbohlav succeeded in 
cultivating the amoeba on an artificial medium in 1925 (Boeck and Drbohlav, 1925), 
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and Diamond in 1961 first established the axenic cultivation of Entamoeba and finally 
in 1978 introduced the monophasic medium, TYI-S-33, which is still in use (Diamond, 
1961; Diamond et al., 1978). 
 
1. 2. 2. Epidemiology  
 
Entamoeba histolytica has a global distribution and it is a significant health risk in 
developing countries and everywhere where poor sanitary conditions predominate 
(Stanley, 2003). The countries with highest incidence are in Africa, Middle and South 
America, the Indian subcontinent and tropical Asia. In developed countries, as well, 
the parasite can cause outbreaks, when the cysts of the parasite contaminate 
drinking water, as happened in Chicago in 1933 when union between sewage and 
tap-water pipes caused at least 800 cases of amoebiasis among hotel guests. A 
similar outbreak happened in Tbilisi, Republic of Georgia, in 1998, when due to 
contaminated municipal water supplies 177 patients had either liver abscess or 
amoebic colitis and four of them died. In developed countries most infections are 
caused by E. dispar and there are certain populations with higher predominance, 
such as travelers and immigrants from endemic areas, homosexual males, as well as 
the institutionalized populations (Barwick et al., 2002; Stanley, 2003; Fauci et al., 
2008; Petri, 1996; Ali et al., 2008). 
    It is estimated that 500 millions or approximately 10% of the human population is 
infected with Entamoeba, however the majority of those infections, around 90%, are 
due to non-pathogenic Entamoeba dispar. Report of the World Health Organization 
(WHO) from 1997 revealed that up to 100,000 people annually die from invasive 
amoebiasis, what makes E. histolytica the third leading cause of death due to a 
parasitic disease, after schistosomiasis and malaria (Walsh, 1986; WHO, 1997; 
Stauffer and Ravdin, 2003; Fauci et al., 2008; Petri, 2008). 
    It has been shown that amoebic liver abscess is predominantly a male disease, 
affecting men between 18 and 50 years of age with rates 3-20 times higher than in 
other populations. Amoebic colitis, however, is still considered an equal-opportunity 
disease, affecting both sexes, adults as well as the children (Acuna-Soto et al., 2000; 
Stanley, 2003).  
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1. 2. 3. Life cycle  
 
E. histolytica has a simple two-stage life cycle. Infection is caused by ingestion of 
fecally contaminated food or water containing cysts of the parasite (Fig. 3 ). The 
cysts are round, 10 –15 µm in diameter, contain four nuclei and are enclosed with a 
refractile wall. After surviving the stomach acid, the cysts travel through the small 
intestine to the terminal ileum or colon, where the excystation takes place (Fig. 3 ). 
Each of the nuclei of the quadrinucleate cyst divides once more, so one cyst forms 
eight highly motile, pleomorphic shaped trophozoites (Stanley, 2003; Diesfeld et al., 
2003; Haque et al., 2003) (Fig. 3 ). The size of the trophozoites varies from 10 to 
50 µm in diameter. They ingest food particles and intestinal bacteria, reproduce by a 
clonal expansion. Their encystation (Fig. 3 ) and the excretion of the new cysts 
completes  the life cycle of the parasite. The trophozoites can be found in the stool, 
however are not able to survive outside the human body for a long time (Fig. 3 )  
and they are not infectious (Stanley, 2003; Stauffer and Ravdin, 2003). 
    In 90% of the cases the trophozoites aggregate in the intestinal mucin layer and 
then encyst so the infection is not causing any symptoms. In 10%, however, the 
infection takes an invasive course, when the trophozoites adhere to the colonic 
epithelium and induce cell lysis. In most cases the infection stays in the intestine 
causing amebic colitis but quite frequently Entamoeba trophozoites spread 
extraintestinally to the liver where they cause large abscesses. In very rare cases, 
further spread to the brain is observed (Haque et al., 2003).  
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Figure 4:  Life cycle of Entamoeba histolytica. From CDC (Centers for Disease Control and 
Prevention, Atlanta, GA, USA; www.dpd.cdc.gov/dpdx)  
 
 
1. 2. 4. Disease and diagnostics 
 
Although, as previously mentioned, 90% of E. histolytica infections are asymptomatic 
and self-limited, in 4–10% of cases the parasite causes amoebic colitis or liver 
abscess, rarely with pulmonary complications or very rarely with a brain abscess 
(Stanley, 2003; Haque, 2003). Patients with amoebic colitis present with abdominal 
pain and tenderness, as well as bloody diarrhea, and after a few days with significant 
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weight loss. Patients may also develop so-called toxic megacolon, which is 
characterized by severe bowel dilation with intramural air (Stanley, 2003; Fauci et al., 
2008). The liver abscess is a result of haematogenous spread of trophozoites 
through the portal circulation to the liver and presents with fever, right upper quadrant 
pain and hepatic tenderness (Stanley, 2003). These patients can also develop 
complications if the amoebic liver abscess ruptures through the diaphragm, causing 
the pleuropulmonary amoebiasis. The illness presents with pleuritic chest pains, 
cough and respiratory distress (Stanley, 2003). Brain amoebic abscess is a very rare 
complication of liver abscess with a variety of symptoms, like headache, vomiting and 
seizures. Almost half of the reported cases had a deadly outcome (Orbison et al., 
1951; Stanley, 2003). 
 
    The diagnosis of E. histolytica colitis relies on three consecutive microscopic 
examinations of properly and freshly prepared stool samples of a patient. This 
method, however, cannot distinguish between E. histolytica and non-pathogenic E. 
dispar, so it is not appropriate as a screening technique in epidemiological studies 
(Healy, 1971; Krogstadt, 1978; Gonzàlez-Ruiz, 1994). There are commercially 
available ELISA assays that identify E. histolytica antigen in the stool and in this way 
also distinguish between pathogenic and non-pathogenic Entamoeba species 
(Haque et al., 2000; Pillai et al.,1999; Stanley, 2003). PCR is more commonly used in 
research and field studies, however, it can be used as a diagnostic method as well 
(Clark and Diamond, 1993; Stanley, 2003). The methods of choice for diagnosis of 
amoebic liver abscess are ultrasound or CT scan. However, although both methods 
are sensitive, they are not absolutely specific for this disease (Stanley, 2003). 
 
1. 2. 5. Metabolism  
 
 Carbohydrate metabolism 
 
E. histolytica has been classified as amitochondriate type I protist (Martin and Müller, 
1998), so the energy generation takes place in cytosol and not in mitochondria, 
although, there is a mitochondrial remnant, called mitosome. The function of the 
mitosome has not been clarified with certainty even after complete genome 
sequencing (Clark et al., 2007). 
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    Entamoeba uses glucose and to a lesser extent some amino acids as energy 
source (Loftus et al., 2005; Clark et al., 2007). Reeves has pointed out in 1984 that 
Entamoeba generates energy by various types of substrate level phosphorylation 
(Reeves, 1984; Clark et al., 2007). Being a gut parasite it has limited oxygen 
availability, so the pathways for ATP synthesis do not have oxygen as a terminal 
electron acceptor on disposal (Tielens et al., 2010). The complete genome 
sequencing revealed, indeed, absence of tricarboxylic acid cycle protein genes, as 
well as, mitochondrial electron transport chain (Loftus et al., 2005; Clark et al., 2007).  
One of the most important enzymes is pyruvate:ferredoxin oxidoreductase (PFOR) 
for a conversion of pyruvate in acetyl-CoA, by utilization of ferredoxin as electron 
acceptor (Reeves et al., 1977; Clark et al., 2007). In mitochondriate organisms after 
the glucose has been broken down to acetyl-CoA, the molecule further enters the 
tricarboxylic acid cycle. Since Entamoeba lacks this pathway the cleavage energy of 
the thioester bond of acetyl-CoA is used by acetyl-CoA synthetase (acetate 
thiokinase) to generate one ATP from ADP and PPi (Reeves et al., 1977; Clark et al., 
2007). The end products of glucose breakdown in Entamoeba are acetate, ethanol 
and carbon dioxide (Tielens et al., 2010).  The energy is stored in glycogen granules 
that can be seen in the cytosol (Takeuchi et al., 1977; Clark et al., 2007). 
    Several genes coding for enzymes of amino acid catabolism were found in the 
Entamoeba genome (Anderson and Loftus, 2005), which is consistent with Reeves´ 
observations that Entamoeba is capable of taking up amino acids (Reeves, 1984) 
and using them for energy generation (Zuo and Coombs, 1995; Clark et al., 2007). 
 
Biosynthesis of amino acids 
 
In the human intestine E. histolytica has access to many host-derived as well as 
bacteria-produced organic compounds, so it lacks any pathway for amino acid 
biosynthesis other than serine and cysteine (Ali et al., 2003, 2004; Nozaki et al., 
1998, 1999; Clark et al., 2007). The two amino acids are probably used for 
production of cysteine, which is the essential intracellular thiol (Loftus et al., 2005; 
Fahey et al., 1984). The high levels of cysteine in the parasite are also likely to make 
up for the lack of glutathione, a major part of oxidative stress resistance in many 
organisms (Fahey et al., 1984; Loftus et al., 2005). 
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Lipid metabolism 
 
As mentioned above Entamoeba lacks oxidative phosphorylation, so the fatty acids 
cannot be exploited as source of energy. The ability of de novo fatty acid synthesis is 
also lost, but the abilities to elongate fatty acids and to synthesize some 
phospholipids are maintained. However, phospholipids as well as the cholesterol, 
which are membrane components, are usually acquired from the food or from the 
human host (Das et al., 2002; Sawyer et al., 1967; Clark et al., 2007; Loftus et al., 
2005). 
 
1. 2. 6. The genome 
 
Completion of the E. histolytica genome in 2005 (Loftus et al., 2005) showed that the 
genome consists of approximately 24 Mb and around 10,000 genes with an average 
size of 1.7 kb. Pulse–field gel analysis indicates 14 chromosomes in E. histolytica 
and a possibly ploidy of four (Willhoeft and Tannich, 1999). Although the majority of 
genes comprise a single exon, there are still 25% of them with introns and 6% that 
contain two or more introns, so the amoeba genome must encode the machinery for 
mRNA splicing, as well. One further unique feature of the Entamoeba genome is the 
organization of tRNA into distinct arrays, the function of which remains still unclear 
(Tawari et al., 2008). 
 
1. 2. 7. Pathogenicity 
 
There are three main virulence factors in E. histolytica: the Gal/GalNAc lectin, 
amoebapores and cysteine proteinases. 
 
 
Gal/GalNAc lectin 
 
Maybe the most important factor in E. histolytica virulence is the Gal/GalNAc lectin, a 
protein that is responsible for adherence to the colonic wall, as well as cytolysis, 
invasion and resistance to the human complement (Mann, 2002; Petri, 2008). 
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It is a heterodimer composed of heavy (170 kDa) and light (35/31 kDa) subunits 
(Petri et al., 1989), as well as a noncovalently linked intermediate subunit (150 kDa) 
(Cheng et al., 2001). The protein binds to N-acetyl-D-galactosamine containing 
structures on the surface of the host cell, as the first step of the process ultimately 
leading to its death (Ravdin and Guerrant, 1981; Petri et al., 1989). It attaches to the 
colonic epithelium and also to the human neutrophils, human erythrocytes and to 
certain bacteria (McCoy et al., 1994; Ravdin et al., 1985; Petri, 2008). 
 
Amoebapores 
 
Cytoplasmic vesicles contain, among others, amoebapores, which are channel-
forming peptides of 77 amino acid residues (Leippe et al., 1992). There are three 
isoforms of amoebapores, A, B and C with a ratio of 35: 10: 1 and a 35% to 57% 
amino acid sequence identity (Leippe et al., 1992; 1994; 1997; Petri, 2008). 
The amoebapores manifest their cytolytic activity by formation of channels within the 
plasma membrane of the target cell, through which water, ions and small molecules 
pass (Leippe et al., 1994). It is also suggested, after in vitro investigations, that E. 
histolytica without amoebapore A is unable to cause pathological effects (Bracha et 
al., 2003).  Furthermore, in vivo, it has been demonstrated that the avirulent E. 
histolytica strain G3 indeed lacks amoebapore A and this is believed to be cause of 
its lack of virulence (Bujanover et al., 2003). 
 
Cysteine proteinases 
 
Cysteine proteinases belong to the papain superfamily and occur in a wide range of 
organisms. E. histolytica has 44 genes encoding cysteine proteinases, whose 
molecular weight lie between 16 kDa and 96 kDa (Clark et al., 2007). It appears that 
most important for E. histolytica pathogenesis are cysteine proteinase-1 (CP1), 
cysteine proteinase-2 (CP2) and cysteine proteinase-5 (CP5), whose functional 
orthologs are absent in non-virulent E. dispar. CP5 is the only proteinase present on 
the surface of amoebae (Bruchhaus et al., 1996, 2003; Jacobs et al., 1998; Willhoeft 
et al., 1999), and it has been shown that it binds to a receptor on colonic cells, an 
αVβ3 integrin, and stimulates a pro-inflammatory response via NFκB (Hou et al., 
2010; Ralston and Petri, 2011). The proteinases of E. histolytica have a strong 
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cytopathic effect on the target cells. By degradation of the components of the extra-
cellular matrix, such as laminin, fibronectin and collagens, they release adherent cells 
from monolayers and facilitate invasion into the colonic mucosa and they also 
degrade secretory IgA and serum IgG (Keene et al., 1986; Stanley, 2003; Haque et 
al., 2003). 
 
 
1. 2. 8. Host immune response 
 
The host responds to E. histolytica by activating both cell-mediated and humoral 
immune response, which can result in either asymptomatic or symptomatic course of 
disease (Stauffer and Ravdin, 2003). When the parasite breaks through a physical 
barrier, the mucin layer, which is the first line of defense, it causes an inflammatory 
response by activating nuclear factor κB (NFκB), which activates intestinal epithelial 
cells to produce interleukin-1β, interleukin-8 and cyclooxygenase-2. These mediators 
attract neutrophils and macrophages to the site of infection. However, E. histolytica 
has the ability to suppress the macrophage respiratory burst and to lyse neutrophils. 
This results in the release of mediators, which cause diarrhea and additional tissue 
damage (Seydel et al., 1997; Stenson et al., 2001; Haque et al., 2003). 
    In how the disease unfolds, amebic virulence factors have more roles.  Due to its 
sequence similarity and cross reactivity to the human leukocyte antigen CD59, the 
Gal/GalNAc-specific lectin is able to inhibit the assembly of the complement C5b-C9 
membrane attack complex (Braga et al., 1992). Amoebic cysteine proteinases 
inactivate and degrade the anaphylatoxins C3a and C5a (Reed et al., 1995) and 
protect amoebae from opsonization by degrading secretory IgA and serum IgG 
(Haque et al., 2003). The cell-mediated response is characterized by a lymphocyte 
proliferation and lymphokine secretion, which are proven to be amoebicidal in vitro 
(Salata et al., 1986; Haque et al., 2003). Some studies suggest a role of CD4+ T-
cells in the outcome of illness in the way that depletion of these cells decreases the 
severity of the disease (Arellano et al., 1996; Houpt et al., 2002). 
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1. 3. Giardia intestinalis 
 
Giardia intestinalis (syn. Giardia lamblia, Giardia duodenalis) is a flagellated, 
unicellular, binucleated protozoan (Fig. 5) that commonly causes diarrheal disease all 
over the world (Adam, 2001; Ali and Hill, 2003). 
 
 
Figure 5: G. intestinalis trophozoites 
 
 
1. 3. 1. Historical overview 
 
G. intestinalis was first described in 1681 by Antonie van Leeuwenhoek, as he was 
conducting microscopical examination of his own diarrheal stool (Dobell, 1920).  
The parasite was more thoroughly described by Vilem Lambl in 1859, however, he 
named it Cercomonas intestinalis, because he was certain that it belongs to the 
genus Cercomonas (Lambl, 1859). First time Giardia was used as genus name, 
when in 1882 Kunstler described a parasite in tadpoles, presumably Giardia agilis 
(Adam, 2001). The name of the parasite was changing, from Lamblia intestinalis 
proposed by Blanchard in 1888, to Giardia duodenalis by Stiles in 1902 and Giardia 
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lamblia by Kofoid in 1915 (Blanchard, 1888; Stiles, 1902; Kofoid, 1915). Today the 
parasite is most commonly called Giardia intestinalis. 
    G. intestinalis was cultivated axenically for the first time in 1970 by Meyer with the 
trophozoites acquired from the rabbit, chinchilla and cat (Meyer, 1970). Today, the 
most commonly used medium for cultivation is Keister´s modified TYI-S-33 medium 
(Keister, 1983). 
 
1. 3. 2. Epidemiology 
 
Giardiasis occurs throughout the world, but especially in regions with poor sanitary 
conditions and with an estimated 2,800,000 cases per year (Wolfe, 1992; Ali and Hill, 
2003). There is still a high morbidity rate, especially among children (Boreham, 1991; 
Upcroft and Upcroft, 1998).  Infection may be caused by ingestion of as few as 10 
cysts of G. intestinalis (Rendtorff, 1954). Cysts are very resilient. They can survive for 
several months in a humid environment with a temperature between 4– 10ºC (Wolfe, 
1992). The infection with G. intestinalis is most commonly the result of ingestion of 
contaminated water, however it can be caused by direct fecal-oral transmission, 
ingestion of contaminated food or person to person transmission (Hill, 1993; Ortega 
and Adam, 1997). Although Giardia infections and especially waterborne outbreaks 
of diarrhea are more common in developing countries, they are frequent in developed 
countries as well (Hill, 1993; Ortega and Adam, 1997). The prevalence of G. 
intestinalis in patients with diarrhea is about 20% in developing countries (Islam, 
1990; Flanagan, 1992), and from 3–7% in developed countries, where is linked 
mainly with waterborne outbreaks or traveling to countries where the parasite is 
endemic (Hoogenboom-Verdegaal et al.,1989; Adam, 1991; Farthing, 1994; Kortbeek 
et al., 1994; Flanagan, 1992), with peaks  at the age groups 1– 4 and 20– 40 
(Flannagan, 1992). 
    Giardia cysts are relatively resistant to the chlorination and ultraviolet light and the 
only effective method to remove them from water is filtration (Hill, 1993; Ortega and 
Adam, 1997). 
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1. 3. 3. Taxonomy and life cycle 
 
Giardia is regarded as one of the most primitive eukaryotic organisms (Sogin et al., 
1989) and belongs to the Phylum Zoomastigophora, Class Zoomastigophorea and 
Order Diplomonadida (Sogin et al., 1989; Ortega and Adam, 1997). The Genus 
Giardia includes six species. Between G. agilis from amphibians, G. muris from 
rodents, reptiles and birds, and G. intestinalis from humans and other mammals 
noticeable differences can be observed already by light microscopy (Ortega and 
Adam, 1997). Another two species, G. ardeae from herons and G. psittaci from 
psittacine birds such as parrots, show morphological differences that can be detected 
by electron microscopy. In this way they can be distinguished from one another and 
from G. intestinalis (Erlandsen and Bemrick, 1987, 1990; Ortega and Adam, 1997). 
G. microti from voles and muskrats differs by a comparison of 18S rRNA sequence 
from G. intestinalis (van Keulen et al., 1998; Adam, 2001). 
    G. intestinalis has a simple life cycle, which consists of two stages: non-motile cyst 
and motile trophozoite. Once ingested (Fig. 5 ), cysts travel to the stomach and 
after being exposed to the acidic environment, they excyst in the small intestine (Fig. 
5 ). Here motile trophozoites replicate by binary fission (Fig. 5 ), and cause 
symptoms of diarrhea and malabsorption. In the jejunum they encyst (Fig. 5 ), 
under exposure to the biliary fluid and through the feces the cysts are passed further 
in the environment (Fig. 5 ) and to the next host (Adam, 2001). 
    The cysts are 5 by 7 to 10 µm in diameter and covered by a cyst wall, whose 
predominant sugar component is an N-acetylgalactosamine homopolymer (GalNAc) 
(Jarroll et al., 1989; Adam, 2001). Trophozoites are teardrop-shaped, 12 to 15 µm 
long and 5 to 9 µm wide with a characteristic ventral adhesive disc, four pairs of 
flagella and a median body (Elmendorf, 2003; Adam, 2001).  
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Figure 6: Life cycle of G. intestinalis. From CDC (Centers for Disease Control and 
Prevention, Atlanta, GA, USA; www.dpd.cdc.gov/dpdx)  
  
 
Genotypes of G. intestinalis 
 
Giardia intestinalis can be divided in seven genotypes (assemblages), of which only 
two (A and B) can infect humans, as well as other mammals and the rest of which are 
causative agents of the disease in dogs (C and D), livestock (E), cats (F) and rats 
(G).  However, recent findings and studies of the WB isolate (assemblage A) and the 
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GS isolate (assemblage B) have shown such large genetic differences between the 
two isolates, that there is ongoing debate whether the two assemblages should be 
reclassificated into two different Giardia species (Caccio and Ryan, 2008; Monis et 
al., 2009; Franzen et al., 2009). 
 
1. 3. 4. Disease and diagnostics 
 
In most cases Giardia infections are asymptomatic. However, if symptomatic, 
infections can be acute or chronic. In acute giardiasis, symptoms occur after 
approximately one to three weeks and include diarrhea with foul-smelling stool, 
malabsorption, abdominal cramps, bloating, belching, nausea and vomiting, as well 
as weight loss, if other symptoms persist (Ortega and Adam, 1997; Fauci et al., 
2008). In chronic giardiasis, symptoms are not so severe and occur in episodes. 
Many patients seek professional help later in the course of the disease, so some 
serious consequences, such as growth retardation and dehydration may occur (Fauci 
et al., 2008). 
    Diagnosis of the disease relies on the identification of the cysts in the stool 
specimens, which have previously been stained with iron-hematoxylin or trichrome 
(Ortega and Adam, 1997). Due to a sporadic cyst passage, the stool samples should 
be examined at least three or even up to six times or should be concentrated by zinc 
sulfate or formalin-ethyl acetate methods (Ortega and Adam, 1997). There are also 
highly sensitive and specific enzyme immunoassay (EIA) kits for detection of Giardia 
spp. antigen in the stool (Marshall et al., 1997; Ortega and Adam, 1997), as well as 
direct fluorescence antibody (DFA) tests, which are used for detection of intact 
organisms in the stool (Ali and Hill, 2003). If there is a strong suspicion of Giardia 
infection that cannot be proven, a string test can be used for a direct examination of 
the intestine. The string test consists of a capsule attached to a string, which is 
swallowed by a patient and withdrawn and examined for trophozoites on the next 
day. Other methods, that are not used so often, are biopsy and gastroendoscopy with 
duodenal aspiration (Beal et al., 1970; Ortega and Adam, 1997).  
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1. 3. 5. Metabolism  
 
Carbohydrate metabolism 
 
Carbohydrate metabolism of G. intestinalis is just like in E. histolytica relying on 
substrate level phosphorylation and due to activities of pyruvate:ferredoxin 
oxidoreductase and 2-ketoacid oxidoreductase, among other enzymes, glucose is 
degraded and metabolized to acetate, ethanol, alanine and carbon dioxide. Under 
strictly anaerobic conditions the main product of glucose breakdown is alanine, in the 
presence of small concentrations of oxygen it is ethanol and under aerobic conditions 
the main products are acetate and carbon dioxide (Brown et al., 1998; Adam, 2001).  
 
Amino acid metabolism 
 
Amino acids play a much bigger role in energy production by Giardia then by 
Entamoeba. Giardia is able to take up alanine, arginine and aspartate from the 
medium (Mendis et al., 1992; Schofield et al., 1990, 1991; Adam 2001). The arginine 
dihydrolase pathway, although more common in prokaryotes, also occurs in Giardia, 
in order to convert arginine to ornithine and ammonia, generating one ATP molecule 
from ADP (Schofield et al., 1990, 1992; Adam, 2001). 
 
Lipid metabolism 
 
Giardia does not have the ability of de novo synthesis of fatty acids, so the required 
cholesterol and phosphatidylcholine are obtained from the environment (Jaroll, 1981; 
Farthing et al., 1985; Gillin et al., 1986; Lujan et al., 1996; Adam, 2001), where bile 
salts are important not only as a source, but also as transporters of lipids to the 
parasite surface (Lujan et al., 1996; Adam, 2001). 
 
 
1. 3. 6. The genome 
 
Giardia intestinalis has two nuclei, which have the same size, DNA amount and 
transcriptional activity (Kabnick and Peattie, 1990; Yu et al., 2002; Ankarklev et al., 
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2010). The genome consists of 12 Mbp with 46% of G+C content. Each nucleus has 
five chromosomes (Adam, 2000), although there are findings, which suggest that in 
some Giardia isolates nuclei show aneuploidy (Tumova et al., 2007). The Giardia 
genome project revealed that the parasite has simplified metabolic pathways in 
comparison to other eukaryotic organisms as well as simplified machinery for DNA 
replication, transcription and RNA processing (Morrison et al., 2007).  
 
1. 3. 7. Pathogenicity 
 
The question why some patients develop symptoms and others do not, although they 
are infected with Giardia, still remains to be answered (Fauci, et al., 2008). 
Trophozoites adhere to the epithelium, however, no tissue invasion is observed. 
There are several theories, why do symptoms occur: villous blunting, lymphocyte 
infiltration, lactose intolerance, as well as malabsorption and diarrhea. One of the 
theories is that the symptoms are an answer to diffuse shortening of the microvillus 
brush border and linked with it loss of enzyme activities (Farthing, 1997; Ortega and 
Adam, 1997; Ali and Hill, 2003; Scott et al., 2004; Buret, 2007; Fauci, 2008; Hodges 
and Gill, 2010). Another theory maintains that it is a reaction by the host immune 
response, that is causing mucosal inflammation after infiltration of lymphocytes and 
mast cells or symptoms could be caused by a reaction to a bile content alteration 
(Ortega and Adam, 1997; Ali and Hill, 2003; Fauci, 2008; Hodges and Gill, 2010; 
Ankarklev et al., 2010). 
 
Virulence factors  
 
The first requirement for developing infection is attachment to the epithelial cells and 
colonization of the small intestine, so the ventral adhesive disc as well as the four 
pairs of flagella, are very important virulence factors (Palm, 2005; Weiland et al., 
2003; Ankarklev et al., 2010). 
     Antigenic variation is the ability of G. intestinalis to switch on or switch off the 
gene expression of the cysteine–rich variant–specific surface proteins (VSP) (Prucca 
and Lujan, 2009; Ankarklev et al., 2010). There are approximately 200 genes coding 
for the proteins of each VSP family in assemblages A and B and no identical VSP 
were detected in two assemblages (Morrison et al., 2007; Franzen et al., 2009; 
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Ankarklev et al., 2010).  The size of the proteins varies between 20 and 200 kDa and 
they are the parasites´ main tool for immune evasion. The giardial surface is 
completely covered with them, but their expression is mutually exclusive. Several 
proteins are expressed at the same time only during switching and differentiation, 
which occurs spontaneously every 6 to 13 generations (Nash et al., 1990; Svärd et 
al., 1998; Prucca and Lujan, 2009; Ankarklev et al., 2010).     
            
1. 3. 8. Host immune response 
 
Since the majority of Giardia infections are self-limiting and asymptomatic, it can be 
concluded that host defense is in most cases very effective (Faubert, 2000).  There 
are natural barriers to parasite colonization of the human duodenum and jejunum. It 
is a very hostile environment presented with mucus layer and digestive enzymes, 
which prevent immediate access to the epithelial cells (Roskens and Erlandsen, 
2002; Roxström-Lindquist et al., 2006). Furthermore, peristalsis of the intestine is 
also a natural way for eliminating the parasite. That is the reason why Giardia is 
constantly reattaching itself (Roxström-Lindquist et al., 2006). Mouse experiments 
have shown that probiotic bacteria have an inhibitory effect on Giardia by increasing 
the production of parasite-specific intestinal IgA and serum IgG (Benyacoub et al., 
2005; Roxström-Lindquist et al., 2006). There are other proteins, such as defensin 
and lactoferrin, which as a part of innate immune system have shown in vitro anti-
giardial activity (Eckmann, 2003).     
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1. 4.  Treatment of amoebiasis and giardiasis - a new drug is needed 
   
There are two groups of drugs used for treatment of E. histolytica infection. One 
group includes poorly absorbed luminal amoebicides, paromomycin, iodoquinol and 
diloxanide furoate, which are able to eradicate trophozoites only from the intestinal 
lumen of a patient, but they are able to prevent spread of infection by eradicating 
cysts (Ravdin and Stauffer, 2005; Pritt and Clark, 2008). This group, however, is 
totally ineffective in the case of amebic colitis and liver abscess, which are treated 
with well-absorbed tissue amoebicides. These drugs are presented as 5-
nitroimidazole family, most of all metronidazole and tinidazole (Powell et al., 1966; 
WHO, 1997; Pritt and Clark, 2008; Orozco et al., 2009). Usual therapy is a 5 to 10–
day course of metronidazol and additional treatment with luminal amoebicides for 
cyst eradication (Pritt and Clark, 2008; Orozco et al., 2009).   
    The 5-nitroimidazole drugs, metronidazole, tinidazole, secnidazole, ornidazole and 
nimorazole are, as well, drugs of choice for the treatment of giardiasis (Ortega and 
Adam, 1997: Orozco et al., 2009). Other drugs, furazolidone, paromomycin and the 
first anti-giardial drug quinacrine are either less effective or like quinacrine have more 
severe side effects (Ortega and Adam, 1997). Albendazole is, however, as effective 
as metronidazol, and some data indicate that its toxicity profile is also more favorable 
(Solaymani-Mohammadi et al., 2010). 
    As stated above, therapy for both protozoans is based on metronidazole and its 
derivates. However, metronidazole is known to cause frequent adverse reactions, 
such as metallic taste, headache, nausea, vomiting, epigastric discomfort and 
diarrhea (Solaymani-Mohammadi et al., 2010). Furthermore, central nervous system 
toxicity, as well as pancreatitis have been reported when metronidazole is 
administrated in high doses (Hill et al., 1984; Roe, 1985; Gardner and Hill, 2001). 
The biggest concern in metronidazole use is the evidence that the drug may be 
carcinogenic in mice and rats (Lindmark and Muller, 1976; Bost RG, 1977; Voogd 
CE, 1981; Gardner and Hill, 2001). The International Agency for Research on Cancer 
(IARC) has listed metronidazole as animal carcinogen and the European Directorate 
for the Quality of Medicine and HealthCare in its Safety Data Sheet has issued a 
warning that metronidazole may cause cancer (IARC, 1987; EDQM, 2010). 
Nevertheless, there is not enough evidence to consider metronidazole a human 
carcinogen. To confirm or dismiss such a statement a more comprehensive study 
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with large number of patients treated with metronidazole and a follow up period of 
more than 20 years would need to be conducted (Bendesky et al., 2002). 
Considering that metronidazole can cross the placenta, a possible teratogenicity and 
the influence on the embryo in the first trimenon has also been debated over the 
years (Cudmore et al., 2004).  
    Another concern is growing resistance to metronidazole, especially of Giardia with 
20% prevalence for clinical resistance and easily acquired laboratory resistance by 
gradual exposure to increased drug concentrations (Upcroft, 2001; Boreham et al., 
1988; Orozco et al., 2009). Furthermore, there have been reports that Giardia after 
failing treatment with metronidazol showed resistance to other known antigiardial 
drugs as well (Brasseur et al., 1995; Orozco et al., 2009). Entamoeba until now did 
not show any capacity to develop metronidazol resistance. However, in laboratory 
conditions by stepwise exposure to elevated drug concentrations partial resistance 
has been induced (Wassmann et al., 1999; Upcroft, 2001; Orozco et al., 2009). The 
only clinical resistance that has been reported was in patients with liver abscesses, 
however those patients have been successfully cured after the therapeutic drainage 
of the abscess (Hanna et al., 2000). 
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2. Materials and Methods 
 
 2. 1. Parasite strains and media 
 
The strains of parasites used in this study were Entamoeba histolytica HM–1:IMSS 
(ATCC 30459) and Giardia intestinalis WB clone 6 (ATCC 50803). The trophozoites 
were cultivated axenically in 40 ml tissue culture flasks (Becton Dickinson Labware, 
NJ, USA), at 36.5ºC in TYI-S-33 media (Diamond et al., 1978), modified by 
Kollaritsch  for E. histolytica and by Keister´s for G. intestinalis (Keister, 1983). With 
current modifications in order to prepare 1 l of medium, 20 g of casein digest 
peptone, 20 g (10 g for G. intestinalis medium) of yeast extract, 10 g of glucose, 2 g 
of sodium chloride, 1 g (2 g) of cysteine hydrochloride, 1 g of dibasic potassium 
phosphate, 0.6 g of monobasic potassium phosphate, 0.2 g of ascorbic acid and 22.8 
mg of ferric ammonium citrate (brown form) are dissolved in 870 ml (900 ml) of 
purified H2O (Milli-Q Integral 5, Millipore, Vienna). The G. intestinalis medium is 
supplemented with 0.75 g of bovine bile (Sigma-Aldrich). The pH is adjusted to 6.85 
for Entamoeba and to 7.0–7.2 for Giardia medium. After the medium has been 
autoclaved for 15 min at 120ºC and cooled down, both media are supplemented with 
10% (v/v) complement-inactivated bovine serum, 10 ml/l penicillin/streptomycin 
antibiotic mixture (Invitrogen) and Entamoeba medium with 30 ml of Diamond Vitamin 
Tween 80 Solution (40x) (Sigma-Aldrich) as well. E. histolytica trophozoites are 
subcultured twice and G. intestinalis trophozoites three times a week. 
 
2. 2. Compounds 
 
Leaves, stem or root barks of tropical plants from Rutaceae, Meliaceae and 
Asteraceae families were collected on several rainforest locations in Thailand and 
Costa Rica and brought to the Institute of Botany in Vienna, where the extracts were 
prepared and the compounds were isolated by preparative column and thin layer 
chromatography (TLC). The purity was evaluated by high performance liquid 
chromatography (HPLC) and nuclear magnetic resonance (NMR) (Greger et al., 
1996; Hofer et al., 2000). All fourteen compounds were dissolved in 100% 
dimethylsulphoxide (DMSO, Sigma–Aldrich) to a stock concentration of 10 mg/ml.  
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2. 3. Susceptibility assays 
 
The parasites were tested in 96-well microtiter plates under anaerobic conditions 
which were established in 1.1 litre plastic air-tight boxes (EMSA GmbH Emsdetten, 
Germany) by use of Anaerocult A (Merck Darmstadt, Germany). The establishment 
of anaerobic conditions in the boxes was tested using the Anaerotest strips (Merck). 
    The quick tests with end concentrations of 2.5 µg/ml and 10 µg/ml of each 
compound and with 40,000 cells/ml as a starting concentration of the protozoans 
were performed in triplicates in 300 µl volumes of media. As controls, untreated cells, 
cells treated with 10 µM of metronidazole and cells treated with DMSO were used. 
The plates were incubated for 24 h and 48 h at 37ºC. The experiments were 
repeated twice with both protozoans. Evaluation was done by transferring cells to 
Eppendorf tubes, concentrating them to 50 µl volumes by centrifugation in a 
microcentrifuge (Galaxy-Mini, VWR), and staining the cells with the same volume of a 
0.4% solution of trypan blue (Sigma-Aldrich) and counting living and dead cells in a 
Bürker-Türk hemocytometer. The cell number per milliliter was determined by 
counting the cells in all 4 x 16 fields in the counting chamber, to get more accurate 
values. This number was then divided by four and multiplied with 10,000. 
    Assays with the compound that had shown activity in the quick tests were 
performed in the same manner, just in more concentrations of the compound,  
1 µg/ml, 2.5 µg/ml, 5 µg/ml, 7.5 µg/ml, 10 µg/ml and 20 µg/ml, respectively. EC50 
and EC90 values of the substance were calculated via log probit analysis available in 
the SPSS 16.0 statistics software suite (SPSS Inc., now part of IBM, Chicago, IL).  
    Assays with metronidazole, as a control drug, were also conducted under the 
same defined conditions; EC50 and EC90 were calculated, so that efficacy of two 
drugs could be compared. 
    Furthermore, trophozoites of E. histolytica and G. intestinalis were cultivated under 
anaerobic conditions in media containing different cysteine concentrations: 0 g/l, 
0.125 g/l, 0.25 g/l, 0.5 g/l and 1 g/l for Entamoeba and 0 g/l, 0.25 g/l, 0.5 g/l, 1 g/l and 
2 g/l for Giardia. Then the susceptibility of the parasites to the active compound at 
concentrations of 0 µg/ml, 1 µg/ml, 5 µg/ml, and 20 µg/ml, respectively, was 
examined as described above in each of the media. 
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2. 4. E. histolytica proteome analysis 
 
Two-dimensional gel electrophoresis (2DE) was performed by an adapted protocol 
for E. histolytica cell extracts (Leitsch et al., 2005). 
     
 Sample preparation  
The cultivated cells were transferred from the 40 ml flasks in 50 ml Falcon tubes, 
centrifuged (700 x g, 5 min), the supernatant was discarded and the pellet was 
washed twice with 20 ml 1x PBS (700 x g, 5 min) and then suspended in 500 µl 
ddH2O, transferred in 2 ml Eppendorf tubes and filled up with 1.5 ml 12% (w/v) 
trichloroacetic acid (TCA) in acetone (at -20ºC). TCA precipitation is very important 
because it destroys protease activity and keeps the salt concentration as low as 
possible, so it will not interfere with isoelectric focusing. The precipitation step should 
last for at least 60 min at -20ºC. The proteins were sedimented at 14,000 rpm for 20 
min at 4ºC (Sigma centrifuge 1-15 PK) and washed twice with 1 ml ice-cold 90% 
acetone (v/v) / 10% ddH2O in order to remove residual TCA, which would disturb 
isoelectric focusing as well. The pellets were air-dried for 30 min and resuspended in 
500 µl of 2DE solubilization buffer (7 M urea, 2 M thiourea, 1% (w/v) DTT, 0.5% (w/v)  
ampholytes 4% (w/v) 3–[(3–cholamidopropyl)dimethylammonio]–1–propanesulfonate 
(CHAPS)). Resolubilization was carried out overnight at 23ºC under mild shaking on 
a thermomixer. After 30 min centrifugation at 14,000 rpm (4ºC) in order to remove 
any residual cell debris, the protein concentration was measured with the Bradford-
Assay (Bio-Rad Laboratories, Vienna, Austria) at 595 nm according to the 
instructions of the provider.   
    For the 17 cm isoelectric focusing (IEF) strips with a pH range between 5-8, 500 
µg/ml of proteins were diluted with 2DE solubilization buffer to a total volume of 400 
µl. Prepared samples were loaded on an IEF tray and covered with at least 2 ml of 
mineral oil in order to prevent evaporation during first the 12 h of rehydratation. 
 
Isoelectric focusing (IEF) 
The PROTEAN IEF System (Bio-Rad Laboratories, Vienna, Austria) was used for 
isoelectric focusing. The program consists of the following steps: 
1. Rehydration 12 h (50 mV) 
2. 250 V, 1 h, rapid slope 
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3. 500 V, 1 h, rapid slope 
4. 2000 V, 2 h, linear slope 
5. 5000 V, 2 h, linear slope 
6. 10000 V, 5 h, rapid slope or 8000 V, 6 h, rapid slope 
 
Strip equilibration 
After IEF the strips were transferred to the plastic tray, washed with ddH2O in order to 
remove mineral oil and immediately equilibrated, although at this point, they can be 
stored at -80ºC as well. Equilibration is preformed in two steps:    
1. reduction of the cysteine groups with 1% dithiothreitol (DTT) 
2. alkylation of the reduced cysteines with 4% iodoacetamide 
The equilibration buffer consists of: 6 M urea, 30% (v/v) glycerol, 2% (w/v) sodium 
dodecyl sulfate (SDS), 50 mM Tris/Cl pH 8.8. Both steps should not take more than 
15 to 20 min in order to prevent protein loss due to diffusion. 
 
SDS-PAGE 
After the large gels for the second dimension were prepared, each equilibrated strip 
was placed on the top of one gel and overlaid with proteinase-free agarose solution. 
The gels were run at 4ºC overnight on 15–25 mA. 
 
Visualization 
Staining was done with Coomassie staining (0.87g Coomassie Brilliant Blue R250 
(Bio-Rad), 45% (v/v) ddH2O, 45% (v/v) methanol, 10% (v/v) glacial acetic acid) for 20 
min on room temperature. The gels were destained in 20% (v/v) methanol and 10% 
(v/v) glacial acetic acid in ddH2O for 2 h, and afterwards washed and kept in ddH2O. 
The staining and destaining steps were carried out on a Belly Dancer shaker (Stovall 
Greensboro, NC USA).  
 
Identification of proteins  
Coomassie-stained protein spots were excised from the gels, treated with trypsin and 
the resulting peptides were analyzed by liquid chromatography and tandem mass 
spectrometry by Dr. Alain Guillot from the PAPPSO (Plateforme d'Analyse 
Protéomique de Paris Sud-Ouest) core facility, Paris, France.   
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Buffers 
 
Lysis buffer: 
7 M urea 
2 M thiourea 
1% (w/v) DTT 
0.5% (w/v) ampholytes 
4% (w/v) CHAPS 
 
4x Resolution buffer for 2nd dimension: 
1.5 M Tris/Cl pH 8.8 
0.4% (w/v) SDS 
 
Equilibration buffer: 
6 M  urea 
30% (v/v) glycerol 
2% (w/v) SDS 
50 mM Tris/Cl pH 8.6 or pH 8.8 (use resolution buffer as stock) 
 
Acrylamide stock 30% (300 ml) 
90 g acrylamide 
2.4 g bisacrylamide 
Take up in 300 ml ddH2O and filter 
 
Second dimension gels (100 ml = 2 large gels) 
40 ml acrylamide 30% (w/v) 
25 ml 4x resolution buffer 
25 ml water 
10 ml glycerol (87%) 
 
Running buffer for second dimension (1litre): 
10 ml of 10% (w/v) SDS 
3 g   Tris 
14 g glycine 
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3. Results 
 
 3. 1. Establishment of the susceptibility assay 
 
In order to conduct the susceptibility assays, it was necessary at first to establish a 
system in which the parasites would grow in 96-well microtiter plates, which had to be 
used because of limited available amounts of extracted compounds (1 mg or less). 
Trophozoites showed normal growth in 24- and 48-well microtiter plates, however 
they could not survive in 96-well plates, incubated at 37ºC for 24 h in a normal 
aerated incubator. Several approaches were tried out: I – the microtiter plate covered 
with parafilm and the lid, II – the candle-box, which is the gold standard in malaria 
field research (Trager and Jensen, 1976), finally III – and IV – two assays which we 
established and in which plates were kept in air-tight plastic boxes under 
microaerophilic and anaerobic conditions.  
    The microaerophilic and anaerobic assays consisted of one airtight plastic box 
(EMSA GmbH Emsdetten Germany) with a volume of 1.1 litres for one microtiter 
plate (Fig. 7). In the box, one half of an Anaerocult A sachet (Merck, Darmstadt, 
Germany) is added to establish anaerobic conditions, or one Anaerocult C sachet 
(Merck) for microaerophilic conditions. Anaerobic conditions were controlled with 
Anaerotest strips (Merck). Different concentrations of the cells: 10,000, 20,000,             
30,000, 40,000 and 50,000 cells/ml were incubated for 24 h at 37ºC. The cells were 
counted and based on results we decided for the best method (Fig. 8). 
 
          
      Figure 7: Test box for anaerobic and microaerophilic conditions  
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Figure 8: Results of the microtiter plate cultivation experiment  
                             I – plate covered with parafilm and the lid 
                            II – plate in a candle box 
                           III – plate under microaerophilic conditions 
                           IV – plate under anaerobic conditions 
 
    It was decided to use the anaerobic assay to conduct the screenings, because we 
found the cell numbers were slightly superior to the microaerophilic assay, and with 
the use of the Anaerotest strips we could test easily that anaerobic conditions were 
indeed established. 
 
3. 2. Results of the susceptibility assays 
 
After conducting quick tests for all of the substances with E. histolytica as well as G. 
intestinalis from the number of living and dead cells for each concentration and the 
control, the growth inhibition percentages (GI), after 24 h and 48 h, were calculated, 
using the formula (Rolòn et al., 2006): 
   
                        GI (%) = [(Gc – Gp) / Gc] x 100  
 
Gc – the mean number of living cells per milliliter in control 
Gp – the mean number of living cells per milliliter at the different drug concentrations 
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 Substance  Entamoeba histolytica 
  GI [%] 24 h  GI [%] 48 h 
   10 µg/ml  2.5 µg/ml  10 µg/ml  2.5 µg/ml 
 Arborinin  15.27  32.42  -33.17  -57.29 
 Arborin  22.92  36.64  -51.53  -34.68 
 Methyldambullin  27.40  13.95  -1.02  -24.39 
 Sakambullin  25.86  8.14  -13.57  -56.81 
 Yukocitrin  11.08  15.79  -41.91  -21.86 
 5-Hydroxynoracronycine  31.09    26.62  26.41  -41.79 
 Zanthobungeanin  28.72  9.71  2.29  -7.05 
 Kokusaginin  8.80  21.43  0    -25.85 
 Methyllacarol          -13.59    2.83  -16.13  -18.93 
 Iso-gamma-fagarine  5.9  27.45  16.07  -28.75 
 Dictamnin  6.2  -5.37  15.71  -6.45 
 Aglafolin  16.30  11.35  7.84  6.73 
 Microminutin           26.50  14.50  -6.59  13.38 
 Methylgerambullin  96.50  48.27  96.78  30.95 
 
Table 1: Results of the susceptibility assays (quick tests) for Entamoeba histolytica 
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 Substance  Giardia intestinalis 
  GI [%] 24 h  GI [%] 48 h 
   10 µg/ml  2.5 µg/ml  10 µg/ml  2.5 µg/ml 
 Arborinin  17.04  5.73  12.16  13.19 
 Arborin  27.76  18.59  9.10  7.52 
 Methyldambullin  54.79  21.24  26.37  3.62 
 Sakambullin  7.21  7.07  10.77  0.65 
 Yukocitrin  7.53  14.90  7.71  3.70 
 5-Hydroxynoracronycine  -2.13  -0.11  18.24  16.05 
 Zanthobungeanin  28.22  0.04  41.11  40.06 
 Kokusaginin  18.36  24.65  36.09  28.87 
 Methyllacarol          27.90  15.84  19.22  26.76 
 Iso-gamma-fagarine  36.25  0.06  2.65  -1.77 
 Dictamnin  24.02    11.77  1.86  0.54 
 Aglafolin  62.58  63.74  73.92  75.35 
 Microminutin            21.48  10.39  -2.98  -5.63 
 Methylgerambullin  96.99  54.14  99.48  36.85 
 
Table 2: Results of the susceptibility assays (quick tests) for Giardia intestinalis 
     
    The results of the susceptibility assays showed that only one of the fourteen 
substances, namely methylgerambullin (Fig. 9), had an effect against both of the 
parasites, by killing 96.78% of E. histolytica and 99.48% of G. intestinalis cells at the 
highest concentration after 48 h. 
 
 
 49
    As methylgerambullin had shown quite promising results not only against E. 
histolytica and G. intestinalis, but also against trypanosomatids and Plasmodium 
falciparum, a contract was given to Selvita Life Sciences Solutions (Krakow, Poland) 
for the chemical synthesis of methylgerambullin. This synthesis was performed 
according to Ikegami et al. (1989) by the following scheme (Fig. 9). The availability of 
sufficient amounts of methylgerambullin allowed further experiments, in particular the 
proteomic studies described below.  
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Figure 9: Chemical synthesis of methylgerambullin 
 
    Assays with both protozoans and different concentrations of methylgerambullin, 
 1 µg/ml, 2.5 µg/ml, 5 µg/ml, 7.5 µg/ml, 10 µg/ml and 20 µg/ml, respectively were 
performed in order to calculate EC50 and EC90 values of the compound after 24 h 
and 48 h of the exposure to the compound. The assays for each parasite were 
repeated three times. EC50 and EC90 with the results of each assay were calculated 
and out of those results the geometric mean (G) was calculated as the final result. 
 
 
 50
Entamoeba histolytica – methylgerambullin 
 
EC90 [µg ml-1] Exp. 1 Exp. 2 Exp. 3                    G  
24 h 16.77 88.23 20.86 31.37
48 h 16.29 258.55 43.53 56.81
 
Table 3: The EC50 and EC90 values of three experiments and calculated geometric mean 
(G) for E. histolytica treated with methylgerambullin 
 
 
Giardia intestinalis – methylgerambullin 
EC50 [µg ml-1] Exp. 1 Exp. 2 Exp. 3                   G 
24 h 27.06 2.94 2.91 6.14
48 h 196.06 4.94 3.73 15.34
 
EC90 [µg ml-1] Exp. 1 Exp. 2 Exp. 3                  G  
24 h 48.53 9.45 6.99 14.74
48 h 3452.68 14.03 9.80 78.00
 
Table 4: The EC50 and EC90 values of three experiments and calculated geometric mean 
(G) for G. intestinalis treated with methylgerambullin 
      
In order to compare EC50 and EC90 of methylgerambullin with those values of 
metronidazole, the drug which is used for the treatment of E. histolytica and G. 
intestinalis infections, the assays with both parasites and metronidazole were 
conducted under same conditions and EC50 and EC90 were calculated. 
 
 
 
 
EC50 [µg ml-1] Exp. 1 Exp. 2 Exp. 3                    G 
24 h 4.31 9.11 5.72 6.08
48 h 4.59 13.77 6.23 7.33
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Entamoeba histolytica – metronidazole (control) 
 
EC50 [µg ml-1]                    Exp. 1                    Exp. 2                     G 
 24 h                       0.32                         0.52                     0.41 
 48 h                       0.15                       0.39                     0.24 
 
EC90 [µg ml-1]                    Exp. 1                   Exp. 2                      G 
24 h                       0.87                        1.24                      1.04 
48 h                       0.56                      0.87                      0.70 
 
Table 5: The EC50 and EC90 values of three experiments and calculated geometric mean 
(G) for E. histolytica treated with metronidazole 
 
 
 
Giardia intestinalis – metronidazole (control) 
 
EC50 [µg ml-1]                    Exp. 1                    Exp. 2                       G 
24 h                       0.59                       0.49                       0.54 
48 h                       0.31                       0.36                       0.33 
 
EC90 [µg ml-1]                     Exp.1                    Exp. 2                       G 
24 h                       1.83                       1.21                       1.49 
48 h                       1.85                       1.01                       1.37 
 
Table 6: The EC50 and EC90 values of three experiments and calculated geometric mean 
(G) for G. intestinalis treated with metronidazole 
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3. 3. The activity of methylgerambullin depends on the cysteine concentration 
in the medium 
 
The experiments described above had shown a rather high variability, in general the 
effect of methylgerambullin was weaker in freshly-prepared media. In order to test if 
the activity of methylgerambullin depends on the concentration of cysteine in the 
medium, five assays with defined concentrations of cysteine and different 
concentrations of methylgerambullin for each parasite were conducted. The results 
indeed show an inverse relation between concentration of the cysteine in the medium 
and the efficacy of the methylgerambullin (Figs 10, 11).  
 
 
Entamoeba histolytica: 
 
Methylgerambullin: 0 µg/ml 1 µg/ml 5 µg/ml 20 µg/ml 
    alive     dead      alive      dead  alive      dead    alive      dead   
Cysteine: 0 g/l  50,000 21,250   23,750 26,250       / 71,250       / 71,250
 0.125 g/l  62,500    31,250   36,250 20,000 5,000 61,250       / 70,000
 0.25 g/l  80,000    27,500 55,000 23,750 28,750 63,750 / 55,000
 0.5 g/l 100,000      26,250 36,250 11,250 35,000 36,250 / 72,500
 1 g/l 146,250    33,750 126,250 27,500 53,750 25,000 2,500 103,750
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Figure 10: Entamoeba histolytica cultivated in medium with different cysteine    
                      concentrations and treated with different concentrations of methylgerambullin 
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Giardia intestinalis: 
    
Methylgerambullin:  0 µg/ml 1 µg/ml 5 µg/ml 20 µg/ml 
  alive dead alive dead alive dead alive dead 
Cysteine: 0 g/l   95,000 13,750   36,250 16,250      / 70,000 / 52,500
 0.25 g/l   88,750 12,500 63,750 23,750 2,500 70,000 / 73,750
 0.5 g/l 146,250 12,500 60,000 15,000 13,750 35,000 / 81,250
 1 g/l 226,250 15,000 145,000 13,750 89,100 14,100 19,100 51,600
 2 g/l 320,000 22,500 271,250 26,250 243,750 23,750 191,250 25,000
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Figure 11: Giardia intestinalis cultivated in medium with different cysteine    
                 concentrations and treated with different concentrations of methylgerambullin 
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3. 4. Comparison of methylgerambullin-treated and untreated E. histolytica by 
two-dimensional gel electrophoresis 
         
In order to observe whether methylgerambullin has any effect on the E. histolytica 
proteome, two-dimensional gel electrophoresis was performed by an adapted 
protocol for E. histolytica cell extracts (Leitsch et al., 2005).  Four 40 ml flasks of the 
culture were incubated at 37ºC for four days, until the culture reached the required 
density. The cells were centrifuged at 700 x g for 5 min, the supernatant was 
discarded and the cells were resuspend in TYI-S-33 medium without cysteine and 
split in two 40 ml flasks. The cells in one flask were treated with 40 µg/ml of 
methylgerambullin and the other ones were used as a control. After 3 h and 30 min, 
when the treated cells were rounded and clearly affected by the compound, both of 
the cell cultures were harvested by centrifugation on 700 x g for 5 min. Extracts from 
the cells were prepared and two-dimensional gel electrophoresis was then performed 
as described above, and the gels were Coomassie-stained. 
 
    The stained gels (Figs. 12, 13) showed that there were four newly induced protein 
signals in E. histolytica treated with methylgerambullin. Tandem mass spectrometry 
(MS) carried out by Dr. Alain Guillot at the PAPPSO core facility identified these 
proteins as isoenzymes of alcohol dehydrogenase (ADH) and isoenzymes of 
pyruvate:ferredoxin oxidoreductase (PFOR). 
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Figure 12: Coomassie-stained gel of untreated E. histolytica cell extract 
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Figure 13: Coomassie- stained gel of E. histolytica treated with 40 µg/ml of 
methylgerambullin. Circled in red are four induced proteins, which cannot be seen on the gel 
of untreated E. histolytica: M1 and M2 spots were identified as isomers of alcohol 
dehydrogenase (ADH) and M3 and M4 spots as isomers of pyruvate:ferredoxin 
oxidoreductase (PFOR). 
 
ADH (M1, M2) 
PFOR (M3, M4)
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4. Discussion 
 
4. 1. Natural products against tropical diseases 
       
Protozoa can cause severe diseases, including malaria, leishmaniosis, Chagas 
disease, sleeping sickness, amoebiasis and giardiasis. All these protozoan infections 
are responsible for misery and death, particularly in tropical countries. In spite of 
various efforts, there are still no protective vaccines available against any of the 
protozoan diseases, and parasite resistance to existing drugs has become a serious 
problem. Furthermore many of the available drugs are old or cause serious adverse 
reactions. Due to lack of financial returns, research in this field is of limited interest to 
pharmaceutical companies. As a consequence, only 13 of 1393 new molecular 
entities authorised between 1975 and 1999 were designated for tropical diseases 
(Trouiller et al., 2002). As mentioned in the Introduction, many pharmaceutical 
companies have dismissed their departments for natural product research, because 
the drug discovery from medicinal plants was seen as more time and money 
consuming than other drug discovery methods (Butler, 2004; Koehn and Carter, 
2005; Balunas and Kinghorn, 2005).  
    Focus of pharmaceutical research and drug development in the 1980s shifted from 
natural products to high-throughput synthesis and combinatorial chemistry, which 
provide a larger amount of produced substances. They are also time- and cost-
effective and do not raise a question of intellectual property rights, as the use of 
natural products does (Harvey, 2008). However, although there are libraries with 
dozen thousands of combinatorial new chemical entities available, only one of those 
molecules, namely sorafenib, a kinase inhibitor, has been approved for treatment of a 
human disease, a renal carcinoma (Newman, 2007). To compare, in only two years 
period, from 2005 to 2007, thirteen natural product-related drugs were approved for 
treatment and five of them were newly discovered chemical classes of drugs (Butler, 
2008; Harvey, 2008). Furthermore, according to the Pharmaprojects database 
(www.pharmaprojects.com)  from March 2008 there are in total 225 natural product 
related drugs at different stages of development, of which 108 are of plant origin 
(Harvey, 2008).  In a recent review Harvey also highlights that in a period from 1994 
to 2010 almost 50% of newly introduced drugs were natural product-related drugs 
(Harvey et al., 2010).  
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    Advances in technology of purification and identification of chemical substances 
derived from natural products made this kind of drug research and development 
again more relevant and interesting not only for the scientist, but for pharmaceutical 
companies as well. One of the greatest improvement happened in the field of 
separation technology, where high performance chromatography methods (Foucault, 
1995; McChesney et al., 2007), as well as more recently, the multi-channel counter- 
current chromatography (CCC) method (Wu et al., 2008) made separation and 
fractionation faster and more efficient. Assigning the chemical structure to the 
isolated compound is the next step in the process, which was especially advanced 
with the development of high field NMR spectrometry (Crosmun et al., 1994; 
Claridge, 1999; McChesney et al., 2007), in particular the two-dimensional NMR 
technique. Mass spectrometry techniques alone and coupled with liquid 
chromatography are broadly used as well. Together with the available data bases of 
mass spectra they add the necessary speed and accuracy to the structure 
elucidation process.  
    All these data suggest that in the field of drug research and development one 
should rely more on natural products screening and possibly combine it with 
combinatory chemistry. An isolated active compound can be a lead to the chemists, 
which could then through different processes, using newest technology and 
accumulated knowledge, further improve it. Such improvements in efficacy, 
selectivity, solubility, better absorption or easier excretion from the organism, could 
make a newly isolated active compound a perfect drug candidate. Some of the 
scientists argue that nature has been combining and choosing the substances with 
specific biological advantages for millions of years and that people should try to learn 
from its wisdom (McChesney et al., 2007).  
 
4. 2. Methylgerambullin against Entamoeba histolytica and Giardia intestinalis 
 
In the present study fourteen plant-derived substances were tested for their activity 
against the microaerophilic protozoan parasites, Entamoeba histolytica and Giardia 
intestinalis. Only the sulphur-containing amide methylgerambullin showed promising, 
high anti-amoebic and anti-giardial activity. The obtained EC50s in E. histolytica were 
6.08 µg/ml after 24 h and 7.33 µg/ml after 48 h in comparison to the standard drug 
metronidazole, which showed EC50s of 0.41 µg/ml after 24 h and 0.24 µg/ml after  
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48 h of treatment. Metronidazole also had lower EC90s with 1.04 µg/ml after 24 h 
and 0.70 µg/ml after 48 h, respectively. The obtained EC90s of methylgerambullin 
against E. histolytica were 31.37 µg/ml after 24 h and 56.81 µg/ml after 48 h of 
treatment. So interestingly, the EC50 and EC90 of methylgerambullin are lower after 
24 h than after 48 h. This could mean that after 48 h at this drug concentration E. 
histolytica trophozoites are able to slightly recuperate. 
    The anti-giardial EC50 of methylgerambullin after 24 h was 6.14 µg/ml and the EC 
90 was 14.74 µg/ml. After 48 h methylgerambullin also showed a higher anti-giardial 
EC50 (15.34 µg/ml) and EC90 (78.00 µg/ml) than after 24 h of treatment. 
Metronidazole was more efficient in G. intestinalis with an EC50 of 0.54 µg/ml and an 
EC90 of 1.49 µg/ml after 24 h as well as EC50 of 0.33 µg/ml and EC90 of 1.37 µg/ml 
after 48 h. All other newly tested compounds did not show any or just marginal 
activity against E. histolytica and G. intestinalis. 
    When we compared the EC50 and EC90 values from three consecutive 
experiments with each parasite, we noted a high variation of EC50 between the 
experiments with G. intestinalis, 2.94 µg/ml, 2.91 µg/ml, and third 27.06 µg/ml. This 
led us to the idea that these variations could be in correlation with freshness of the 
used cultivation medium. After a new bottle of the medium has been opened, it is 
kept in the refrigerator for a few days, until is used up. There is a noticeable 
difference as the Giardia medium changed colour from light to dark yellow and the 
Entamoeba medium from light to dark brown. This colour change could be caused by 
the depletion of cysteine.  
    In order to test whether cysteine is important for methylgerambullin activity 
additional experiments with both parasites, cultivated in medium with different 
cysteine concentrations and treated with methylgerambullin, were conducted. The 
results, indeed, showed an inverse relation between methylgerambullin activity and 
concentration of cysteine. We looked at the cysteine concentrations of 0.5 µg/ml for 
Giardia and 0.25 µg/ml for Entamoeba, which are both four times lower than 
concentrations normally used for preparing the medium. At these concentrations 
trophozoites have enough cysteine to grow and divide, so during the Giardia 
experiment the cell concentration tripled and it doubled in the Entamoeba 
experiment. For both parasites the highest concentration of 20 µg/ml of 
methylgerambullin was effective, by killing all the cells, and even lower 
concentrations of 5 and 1 µg/ml showed efficacy. However, in the experiments with 
 60
the highest concentrations of cysteine in the medium, methylgerambullin even in the 
highest concentration of 20 µg/ml was not effective. This led us to believe that 
cysteine reacts with methylgerambullin (Fig. 14) and in this way blocks it, so the cells 
are protected, when there is enough cysteine in the medium. Furthermore, we 
presume that using the same mechanism, methylgerambullin could interact with the 
thiols of the parasite, what could be potentially important for its mode of action and 
the way it destroys the cells.  
 
 
Proposed reaction: 
 
 
Figure 14: Proposed reaction scheme for the reaction of methylgerambullin with cysteine 
 
    Cysteine (Cys) is a non-essential amino acid, however, it is very important for the 
cell function of prokaryotes as well as the eukaryotes, where it plays an essential role 
in maintenance of the redox state of the plasma proteins (Jones et al., 2000; Nkabyo 
et al., 2006). In the mammalian gut lumen glutathione (GSH), which is generated 
from cysteine, has a protective role. Its antioxidant character diminishes the damage 
caused by electrophiles (Martensen et al., 1990; Aw et al., 1992; Dahm and Jones, 
1994; Nkabyo et al., 2006). The total concentration of cysteine, homocysteine and 
glutathione was determined as 35.4 nmol/mg protein in proximal colonic mucosa and 
32 nmol/mg protein in distal colonic mucosa (Morgenstern et al., 2003). Although we 
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definitively expect methylgerambullin to be active in an environment like the human 
gut, this activity could be diminished by the thiols in this environment.  
    When we compared the protein patterns of untreated Entamoeba and Entamoeba 
treated with methylgerambullin by two-dimensional gel electrophoresis, the analysis 
revealed specific differences. As it can be seen in Fig. 13, circled in red, there are 
four additional spots on the gel of the treated cells. Mass spectrometry revealed that 
spots M1 and M2 are isoenzymes of alcohol dehydrogenase (ADH) and spots M3 
and M4 isoenzymes of pyruvate:ferredoxin oxidoreductase (PFOR). These proteins 
are normally to be seen at a more basic pI. The reason why they could have shifted 
to more acidic pI remains to be discovered. One of the theories is that the enzymes, 
through treatment of Entamoeba with methylgerambullin, were phosphorylated and 
due to this modification the position of the enzymes in the gel changed.  
    A possible phosphorylation could also change the activity of the enzymes. ADH 
and PFOR are both part of the glucose catabolism pathway and every change in their 
conformation, which changes their activity, could also influence levels of ATP in the 
cell. Drastical decrease of ATP levels could lead to the cell death. 
    According to the Entamoeba genome project there are more than 150 kinases as 
well as more than 100 putative phosphatases in Entamoeba so protein 
phosphorylation could be important for many activities in the cell (Clark, 2007). 
 
4. 3. Properties of methylgerambullin 
 
So far, methylgerambullin could only be extracted from the genus Glycosmis, family 
Rutaceae, in contrast to other sulphur-containing amides, which also occur in the 
genus Raphanus, family Brassicaceae (Moon et al., 2010). A specimen of glycosmis, 
also called orangeberry, is shown in Fig. 15. To obtain more of the compound, an 
efficient, high-yielding method to chemically synthesize methylgerambullin was found 
(Obwaller et al., unpublished). Chemical synthesis is of high interest and has big 
advantages, like lower costs, batch to batch consistency and purity. Further 
advantages are that chemical synthesis is less time consuming than extraction and 
purification and a constant yield can be achieved, therefore it is easier to establish 
GMP standards for synthetic compounds than for extracted compounds.  
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Figure 15:  Glycosmis sp. (source: Botanical garden, Vienna)  
 
        What is also of great importance is that methylgerambullin can easily be 
dissolved in the non-toxic polyethylene glycol (PEG) in a concentration as high as 10 
mg/ml, overnight. Methylgerambullin, as well as all the other tested compounds, 
obeys the famous Lipinski´s “Rule of Five”, which predicts passive oral absorption of 
the drug in regard to its molecular weight, H-bond donors and acceptors and log-P. 
These are important requirements for further in vivo and other pharmacological 
studies. 
    The sulphur-containing acid moieties of the structure are most likely derived from 
the amino acid cysteine, whereas the amine parts are mostly characterized by 
phenethyl or phenylethenyl groups that additionally can be linked to various 
prenyloxy structures, e.g. in methyldambullin and sakambullin, or geranyloxy groups, 
e.g. in methylgerambullin. These prenylated amides are mostly oxidized to sulfones 
or sulfoxides (Hofer et al., 2000). 
    Several sulphur-containing amides are reported to have anti-fungal or insecticidal 
activity (Greger et al., 1996). Methylgerambullin showed cytostatic activity in CEM-SS 
(T-lymphoblastic leukaemia), KU812F (chronic myelogeneous leukaemia), HT29 
(colon cancer) and UACC-62 (melanoma) cell lines, however, methylgerambullin has 
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been shown to be non-toxic in peripheral blood mononuclear cells (Mohamed et al., 
2004).     
    In another study, the three sulphur-containing amides involved in the present 
study, namely methyldambullin, methylgerambullin and sakambullin, showed high 
activity against Trypanosoma cruzi Y in vitro (Astelbauer et al., 2010) and all three 
compounds were significantly more effective, with lower EC50s and EC90s, than 
benznidazole, the standard drug in the treatment of Chagas disease. After 72 h 
treatment, all three compounds also had lower EC90s than amphotericin B, another 
drug that is used in the treatment of Chagas disease. As against E. histolytica and G. 
intestinalis in the present study, methylgerambullin was demonstrated to be the most 
efficient anti-trypanosomal compound with the lowest EC90, namely 1.92 µg/ml after 
72 h of treatment, compared to amphotericin B with 15.54 µg/ml (Astelbauer et al., 
2010). Interestingly the other two sulphur-containing amides which also showed high 
anti-trypanosomal activity, namely methyldambullin and sakambullin, did not show 
any anti-amoebic or anti-giardial activity in the present study. 
    Furthermore, in the study conducted with 43 fresh isolates of P. falciparum, 
measuring the inhibition of schizont maturation in vitro, methylgerambullin achieved 
total schizont maturation inhibition with an IC50 of 14.29 ng/ml and an IC90 of 118.5 
ng/ml (Astelbauer et al., unpublished). 
    Additionally, we demonstrated promising, high in vitro activity of methylgerambullin 
against promastigote L. infantum MCAN/ES/89/IPZ 229/1/89, Zymodeme MON 1 with 
EC50s of 0.97 µg/ml and 0.20 µg/ml and EC90s of 0.58 µg/ml and 0.45 µg/ml after 
24 h and 48 h of treatment, respectively (Astelbauer et al., unpublished). Therefore, 
methylgerambullin was again the most efficient newly tested compound like in E. 
histolytica and G. intestinalis. Methylgerambullin was even more efficient than the 
control substance miltefosine, which showed EC50s and EC90s with concentrations 
of 0.73 µg/ml, and 3.85 µg/ml after 24 h and 0.52 µg/ml and 0.94 µg/ml after 48 h of 
treatment, respectively. 
    No anti-bacterial or anti-fungal activity has been observed for methylgerambullin 
(Abdullah et al., 2006). In further experiments, no anti-trichomonal activity of any of 
the plant-derived substances included in the present study was observed (Astelbauer 
et al., unpublished). 
    Further in vitro studies towards Plasmodium vivax (Astelbauer et al., in press) and 
fungi including yeasts, e.g. Candida albicans (ATCC 90028) and C. glabrata (ATCC 
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90030) as well as conidials and sporangiospores, e.g. Aspergilus fumigatus III/191 
LP Jan/2007, Rhizopus oryzae III 122, Fusarium solani III/100 (LP) were evaluated 
recently (Willinger et al., unpublished). 
    It is interesting to observe how the exact structure of methylgerambullin plays an 
important role in its activity. If we compare it to metronidazole and other 5-
nitroimidazole drugs which are used in the treatment of a variety of parasitic and 
bacterial diseases, we can see that regardless of their side chain all the drugs of this 
group show high efficacy. In contrast, sulphur-containing amides differ in the way that 
every change in their side chain changes the efficacy of the compound. So we found 
that all three sulphur-containing amides were effective against T. cruzi, two against 
P. falciparum, namely methylgerambullin and sakambullin, two against Leishmania 
spp., methyldambullin and methylgerambullin and only methylgerambullin against G. 
intestinalis and E. histolytica. Since it is obvious that the exact structure of 
methylgerambullin plays an important role in its activity, it remains an open question 
whether the efficacy of the compound could be further improved by modifications of 
the side chains that could be introduced by chemical synthesis.  
    Finally, we presume that the mode of action of metronidazole and 
methylgerambullin are different. If methylgerambullin might sometimes become 
available as a commercial drug, especially against Trypanosoma and Leishmania, it 
could also be used against metronidazole-resistant G. intestinalis or E. histolytica. 
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5. Abbreviations 
2DE two-dimensional gel electrophoresis 
ADH alcohol dehydrogenase 
CCC counter-current chromatography 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio] -1- propanesulfonate 
ddH2O "doubly distilled" water - molecular biology grade water from Millipore 
 system 
DFA direct fluorescence antibody 
DMSO dimethylsulphoxide 
DTT dithiothreitol 
EDQM European Directorate for the Quality of Medicines &HealthCare 
EIA enzyme immunoassay 
GMP Good Manufacturing Practice 
GSH glutathione 
HPLC high performance liquid chromatography 
IARC International Agency for Research on Cancer 
IEF isoelectric focusing 
MS mass spectrometry 
NCEs new chemical entities  
NCI National Cancer Institute 
NMR nuclear magnetic resonance 
PAGE polyacrylamide gel electrophoresis 
PAPPSO  Plateforme d'Analyse Protéomique de Paris Sud-Ouest 
PBS phosphate buffered saline 
PEG polyethylene glycol  
PFOR pyruvate:ferredoxin oxidoreductase 
SPSS Statistical Package for the Social Sciences 
SDS sodium dodecyl sulphate 
TCA trichloroacetic acid 
TCM traditional Chinese medicine 
TLC thin layer chromatography 
USDA United States Department of Agriculture 
VSP variant-specific surface proteins  
WHO World Health Organization 
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